200,000 Shares in The Chemours Company $CC Purchased by Bruce & Co. Inc.

Key Points

• Bruce & Co. Inc. invested approximately $2.71 million in The Chemours Company, acquiring 200,000 shares and marking Chemours as its 22nd largest holding.
• Wall Street analysts have given mixed ratings on Chemours, with targets being reduced by firms like Barclays and Goldman Sachs, while others have maintained a "buy" rating.
• Despite reporting a 5% increase in quarterly revenue, Chemours' stock has dropped 4.5% recently, and the company also announced a reduction in its quarterly dividend.

Bruce & Co. Inc. purchased a new position in The Chemours Company (NYSE:CC - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 200,000 shares of the specialty chemicals company's stock, valued at approximately $2,706,000. Chemours comprises 0.9% of Bruce & Co. Inc.'s investment portfolio, making the stock its 22nd largest position. Bruce & Co. Inc. owned approximately 0.13% of Chemours at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in Chemours in the first quarter worth $822,000. Principal Financial Group Inc. increased its position in Chemours by 116.3% in the first quarter. Principal Financial Group Inc. now owns 742,119 shares of the specialty chemicals company's stock worth $10,041,000 after purchasing an additional 399,097 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Chemours by 22.4% in the first quarter. Janney Montgomery Scott LLC now owns 31,886 shares of the specialty chemicals company's stock worth $431,000 after purchasing an additional 5,843 shares during the last quarter. GAMMA Investing LLC increased its position in Chemours by 1,115.2% in the first quarter. GAMMA Investing LLC now owns 18,617 shares of the specialty chemicals company's stock worth $252,000 after purchasing an additional 17,085 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in Chemours by 8.7% in the first quarter. Bessemer Group Inc. now owns 38,554 shares of the specialty chemicals company's stock worth $522,000 after purchasing an additional 3,081 shares during the last quarter. Institutional investors own 76.26% of the company's stock.

Chemours Trading Down 0.6%

CC stock traded down $0.10 during mid-day trading on Tuesday, reaching $15.12. 586,996 shares of the stock traded hands, compared to its average volume of 3,562,809. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. The Chemours Company has a one year low of $9.13 and a one year high of $22.38. The stock has a market capitalization of $2.26 billion, a PE ratio of -5.40 and a beta of 1.61. The business has a 50-day moving average price of $12.99 and a two-hundred day moving average price of $12.85.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts expect that The Chemours Company will post 2.03 EPS for the current year.

Chemours Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be issued a $0.0875 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.3%. Chemours's dividend payout ratio is presently -12.50%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CC shares. Morgan Stanley reduced their price target on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Royal Bank Of Canada boosted their price target on shares of Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Thursday, July 3rd. Barclays cut their price objective on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 28th. UBS Group cut their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their price objective on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Chemours presently has an average rating of "Moderate Buy" and an average price target of $17.38.

Insider Transactions at Chemours

In related news, insider Damian Gumpel purchased 13,400 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were purchased at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the completion of the acquisition, the insider owned 123,879 shares in the company, valued at approximately $1,142,164.38. This trade represents a 12.13% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Denise Dignam purchased 4,068 shares of the business's stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the acquisition, the chief executive officer owned 191,546 shares of the company's stock, valued at approximately $2,310,044.76. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 25,290 shares of company stock worth $250,437. Company insiders own 0.34% of the company's stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.